Clinical Trials Logo

Filter by:
NCT ID: NCT03376776 Completed - Macular Disease Clinical Trials

Epiretinal Proliferation in Eyes With Full Thickness Macular Hole

Start date: March 2013
Phase: N/A
Study type: Observational

We evaluated preoperative and postoperative optical coherence tomograpghic images in eyes with full thickness macular hole (FTMH) whether the epiretinal proliferation (EP) was detected and detection of EP was correlated to the visual improvement.

NCT ID: NCT03376698 Completed - Clinical trials for Coronary Artery Disease

Dose-finding Study of Colchicine in Type 2 Diabetic Patients With Coronary Artery Disease

DRC-04
Start date: June 15, 2017
Phase: Phase 2
Study type: Interventional

This study is designed to investigate dose-dependent effects of low dose colchicine on inflammatory responses, endothelial function in type 2 diabetic patients with coronary artery disease and leukocyte activation. This study also tested the relationship between doses and safety issue such as incidence of diarrhea. Eligible patients will be randomly allocated to three treatment group: colchicine at 0.5mg per day, 0.25mg per day or placebo for 12 weeks in a double blind , parallel group design. High sensitive-CRP at 4 weeks as primary end point and flow mediated vasodilatation at 12 weeks as the secondary end point will be measured.

NCT ID: NCT03375632 Completed - Clinical trials for Hyperuricemia With or Without Gout

Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)

Start date: January 4, 2018
Phase: Phase 1
Study type: Interventional

To investigate the pharmacodynamics and safety of FYU-981 administered orally once a day for 14 weeks, to uric acid-overproduction type or uric acid-underexcretion type of male hyperuricemic outpatients with or without gout.

NCT ID: NCT03375203 Completed - Insomnia Disorders Clinical Trials

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

Start date: November 23, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this 2 month phase 2b study is to investigate the dose response of 3 doses of JNJ-42847922 (Seltorexant) (5,10 and 20 mg) compared to placebo and zolpidem on sleep onset and maintenance and to further document safety and tolerability of JNJ-42847922 (Seltorexant) upon multiple (14 days) dose administration in participants with insomnia disorder.

NCT ID: NCT03374488 Completed - Clinical trials for UC (Urothelial Cancer)

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

Start date: December 22, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo as a treatment for recurrent or progressive metastatic urothelial carcinoma in patients who have failed a first-line platinum-containing chemotherapy regimen for advanced/metastatic disease.

NCT ID: NCT03373461 Completed - IgA Nephropathy Clinical Trials

Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation

Start date: February 7, 2018
Phase: Phase 2
Study type: Interventional

Efficacy and safety of LNP023 in IgAN patients

NCT ID: NCT03373383 Completed - Clinical trials for Drug-resistant Epilepsy

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

ARISE
Start date: February 12, 2018
Phase: Phase 2
Study type: Interventional

The purpose of the study is to characterize the dose-response relationship with respect to efficacy of Padsevonil administered concomitantly with up to 3 anti-epileptic drugs (AEDs) for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy.

NCT ID: NCT03372837 Completed - Clinical trials for Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL

Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

Start date: January 15, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy of SyB L-0501 in combination with rituximab in patients with recurrent/relapsed diffuse large B-cell lymphoma.

NCT ID: NCT03372200 Completed - Clinical trials for Hyperuricemia With or Without Gout

Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

Start date: January 9, 2018
Phase: Phase 3
Study type: Interventional

FYU-981 or Febuxostat are administrated to hyperuricemia patients (underexcretion and mixed types) with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose regimen.

NCT ID: NCT03370640 Completed - Schizophrenia Clinical Trials

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).

Start date: November 29, 2017
Phase: Phase 1
Study type: Interventional

This is a multiple oral dose, open-label study to assess the safety, tolerability, and pharmacokinetics of SEP-363856 in Japanese subjects with schizophrenia.